Ads
related to: editas medicine stock
Search results
Is Editas Medicine Stock a Buy Now?
Motley Fool· 11 months agoInvestors tend to move away from somewhat speculative stocks when the economic going gets rough. Editas Medicine's most advanced candidate is EDIT-301,...
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
Zacks via Yahoo Finance· 1 year agoFor those looking to find strong Medical stocks, it is prudent to search for companies in the group...
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
Motley Fool via Yahoo Finance· 5 months agoInvesting in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but...
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
Motley Fool· 1 year agoAfter a tumultuous 2022, growth stocks have started to regain their footing in 2023. Small- and...
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%
Simply Wall St. via Yahoo Finance· 1 month agoKey Insights Significantly high institutional ownership implies Editas Medicine's stock price is...
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
Motley Fool via Yahoo Finance· 3 months agoShares of Editas Medicine (NASDAQ: EDIT) charged sharply higher this week, soaring as much as 41.6%,...
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Motley Fool via Yahoo Finance· 4 weeks agoClinical-stage biotech Editas Medicine (NASDAQ: EDIT) delivered quarterly results that fell well...
Why Editas Medicine Stock Is Soaring Today
Motley Fool· 8 months agoWhat happened Shares of Editas Medicine (NASDAQ: EDIT) were soaring 11.2% higher as of 10:41 a.m. ET on Friday after vaulting as much as 24% earlier in...
Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ...
GuruFocus.com via Yahoo Finance· 7 months agoEditas Medicine Inc (NASDAQ:EDIT) reports a net loss of $45.0 million for Q3 2023, down from $55.7...
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool via Yahoo Finance· 4 months agoEditas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few...